ADA 2020: US Pivotal Trial Data Support Medtronic’s Next-Gen Insulin Pump
Clinical data presented during the virtual ADA meeting show Medtronic’s MinMed 780G hybrid closed-loop insulin system, an upgraded version of the company's 770G system, improved patients’ ability to keep their blood-glucose levels within target range.
You may also be interested in...
Tandem Diabetes Care and Medtronic have signed a patent cross-license agreement that paves the way for joint development of future diabetes products and services while avoiding potential legal disagreements.
Medtronic plans to rapidly expand its diabetes technology research and development with $337m in new funding from global investment firm Blackstone Life Sciences.
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.